Cardiovascular Manifestations Of Chronic Kidney Disease

Epidemiology

A common cause of unexpected death is arrhythmias, which are abnormal heart rhythms that can impair normal cardiac function. Pacemakers and defibrillators are examples of interventions that may be used in the diagnosis and treatment process, along with a variety of cardiac monitoring techniques which is an enlargement of the left ventricle of the heart. This hypertrophy is frequently linked to conditions including anemia, fluid overload, and hypertension. An essential part of managing end-stage renal disease (ESRD) is treating the underlying causes and starting renal replacement therapy.

One noteworthy situation in Congestive Heart Failure (CHF) instances is normal Ejection Fraction (EF), which indicates intact pumping function. Nevertheless, diastolic dysfunction, which hinders the heart's capacity to relax and fill correctly, is the root cause of heart failure. Fluid buildup, a sign of circulatory congestion, is a contributing factor to symptoms like edema and dyspnea. Treatments for congestive heart failure (CHF) frequently include lifestyle changes, heart-function-targeting drugs, and treating underlying diseases such as valvular heart disease or hypertension. Effective management of these disorders requires individualized medical evaluation and intervention by healthcare specialists.

Reversed or Confounded Epidemiology  Contradictory Finding

CKD patients with wasting and inflammation have poor survival rates. The association between obesity, hypercholesterolemia, hypertension, and bad outcomes in the general population is inverted in these patients.
Higher BMI is better than lower BMI.

Etiology and Risk Factors

Lipid Abnormalities

CKD patients and Hemodialysis - Has normal cholesterol, Increased triglycerides and Decreased HDLs

Risk Factors

Sources of Elevated Oxidative Stress

Risk factors for CVS disease in CKD

Incidence of CVS events in patients with or without CKD

Clinical manifestations

Chest pain in individuals with renal impairment may be a sign of several cardiovascular problems. A notable trend in patients with chronic kidney disease (CKD) is that acute myocardial infarction (MI) and coronary heart disease frequently show as direct manifestations of MI rather than acute angina. Peripheral artery disease is a risk factor for CKD patients receiving dialysis, especially those with diabetes and pre-existing atherosclerosis. This raises the burden of cardiovascular disease overall. 

Further cardiovascular issues in chronic kidney disease (CKD) include atrial fibrillation and cerebrovascular illness, which emphasize the wide range of problems related to reduced kidney function. The impact on neurological health is shown by the association between renal illness and cognitive impairment.

In CKD, left ventricular hypertrophy and remodeling show promise as strong predictors of death. Recurrent volume overload, widespread ischemia damage, and left ventricular dilatation can result from severe left ventricular hypertrophy. Commonly utilized in dialysis, high-output arteriovenous fistulas increase the risk of myocardial stunning, intradialytic hypotension, and eventually greater mortality rates by causing left ventricular hypertrophy. The extracellular volume overload, salt excretory capacity reduction, and recurrent hypervolemia in chronic kidney disease (CKD) further exacerbate the cardiovascular profile.

Potential side effects include pericarditis, which can arise from untreated uremia and frequently calls for heparin-free dialysis. The complexity of cardiovascular problems in chronic kidney disease (CKD) is exacerbated by infections, fistula recirculation during under-dialysis, underlying illnesses such as systemic lupus erythematosus (SLE), and autonomic dysfunction with decreased baroreflex sensitivity and increased sympathetic nerve activity. 

There are also valve disorders to take into account, the more frequent of which is calcific aortic stenosis. Arrhythmias can result in abrupt cardiac arrest, and catheter use raises the risk of infectious endocarditis. When it comes to controlling these cardiovascular problems in CKD, statins might not be very helpful.

The potassium concentration of the dialysate is an important consideration; a low potassium dialysate is linked to an increased risk, particularly in hemodialysis (HD) patients. When starting dialysis, the risk is higher for HD than for peritoneal dialysis (PD); however, after three years, the risk is higher for PD. This highlights the importance of continuous monitoring and specialized therapies in the treatment of cardiovascular problems in patients with chronic kidney disease (CKD) receiving dialysis.

Diagnosis and Differential Diagnosis

Measuring blood pressure (BP) is essential for treating individuals with chronic kidney disease (CKD), especially those receiving dialysis. A more thorough understanding of a patient's blood pressure trends during the day and at night is possible with ambulatory blood pressure monitoring, which enables a more accurate assessment of the patient's cardiovascular health. 

According to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, electrocardiography (ECG) and echocardiography should be used to assess cardiovascular health in patients with chronic kidney disease (CKD). After reaching dry weight targets, routine echocardiograms are recommended for all patients; the first evaluation should take place one to three months after dialysis starts. Echocardiograms are usually arranged on the day of the interdialytic procedure and then every three years after that.

The guidelines also stress how critical it is to assess individuals with congestive heart failure (CKD) who have an ejection fraction (EF) of less than 40% for coronary heart disease (CHD). As people with lower EF may be more susceptible to cardiovascular problems, this advice highlights the importance of a complete evaluation of cardiac function.
Following these guidelines for routine electrocardiography and echocardiogram monitoring enables medical personnel to monitor changes in the structure and function of the heart over time.

This allows for early detection and intervention in the management of cardiovascular problems in patients with chronic kidney disease (CKD). The overall objectives of enhancing patient outcomes and lowering the risk of cardiovascular events in this susceptible group are in line with this proactive strategy.

Stress test and Screening Renal Transplantation Candidates

ESRD - not suitable for stress echo

• Dobutamine stress echo
• Scintigraphic techniques 

Management of CAD in CKD Patients

Dyslipidemia - KDIGO Guidelines

These guidelines outline a risk-based approach to the use of statin therapy in the management of cardiovascular health in individuals with chronic kidney disease (CKD) and related conditions. Here's a summary:

1. Adults > 50 years with eGFR < 60 (G3a-G5):
   • Recommendation: Initiate statin therapy or statin combined with ezetimibe.
   • Rationale: This group, with reduced kidney function, is considered at increased cardiovascular risk, and statin therapy aims to manage cholesterol levels and reduce cardiovascular events.
2. Adults > 50 years with eGFR > 60:
   • Recommendation: Initiate statin therapy.
   • Rationale: Even with relatively preserved kidney function, individuals in this age group may still benefit from statin therapy to manage cardiovascular risk.
3. Adults 18-49 years with CKD, consider statin if they have more than one of the following: a. Known coronary disease b. Diabetes mellitus c. Prior ischemic stroke d. Estimated 10-year incidence of coronary death or non-fatal MI > 10%
   • Rationale: Even in younger adults with CKD, the presence of additional cardiovascular risk factors warrants consideration of statin therapy to mitigate the risk of cardiovascular events.
4. Dialysis-dependent CKD:
   • Recommendation: Do not start statin or ezetimibe.
   • Rationale: The evidence suggests that the benefits of statin therapy may not outweigh potential risks in individuals on dialysis, and therefore, it is not recommended to initiate statins in this population.
5. Patients already receiving statin at the time of initiation of dialysis:
   • Recommendation: Continue statin therapy.
   • Rationale: For patients already on statin therapy prior to initiating dialysis, it is recommended to continue the treatment to maintain cardiovascular health.
6. Adult kidney transplant recipients:
   • Recommendation: Treat with a statin.
   • Rationale: Individuals who have undergone a kidney transplant are at increased cardiovascular risk, and statin therapy is recommended to manage this risk and promote cardiovascular health.

Coronary Angiography

1. Inducible Myocardial Ischemia:
   • Inducible myocardial ischemia refers to a condition where the blood supply to the heart muscle is insufficient during periods of increased demand, such as physical activity or stress. It is often detected through stress testing, where the heart is subjected to increased workload, and any resulting ischemia can be identified through changes in imaging or electrocardiogram (ECG) patterns. Inducible myocardial ischemia is a sign of compromised blood flow to the heart and can be an indicator of coronary artery disease.
2. Acute Coronary Syndrome (ACS):
   • Acute Coronary Syndrome is a term used to describe a spectrum of conditions that result from a sudden reduction in blood flow to the heart. This reduction is typically caused by the rupture of a plaque in a coronary artery, leading to the formation of a blood clot. ACS includes conditions such as unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). Prompt medical attention and intervention are crucial in ACS to minimize heart muscle damage.
3. Left Ventricular Ejection Fraction (LVEF) < 40%:
   • LVEF is a measure of how well the left ventricle of the heart is pumping blood with each contraction. A low LVEF indicates reduced heart function. An LVEF less than 40% suggests impaired systolic function and is often associated with conditions such as heart failure. Monitoring LVEF is important in assessing cardiac function and guiding treatment decisions, as it is a key parameter used in categorizing heart failure severity.

Investigation   

• Vascular calcification 
• Conventional x-ray
• Multislice spiral CT
• Biomarkers 
• BNP
• NT-ProBNP
• Cardiac troponins 
• FGF-23 

Treatment and Prevention of Cardiovascular Disease

Revascularization 

Individuals undergoing anatomically appropriate internal mammary gland CABG surgery who have multivessel CHD. Less than six months to live – PCI. CBAG provides little benefit if the left internal mammary artery is not used in conjunction with a surgical plan.

PCI in Patients with Limited Life Expectancy: PCI is the process of opening restricted or obstructed coronary arteries by inserting a stent or carrying out additional treatments using a catheter. Compared to CABG, this technique is less invasive. Due to its faster recovery period and less invasiveness, PCI may be selected if a patient has a restricted life expectancy (less than six months).

The Benefit of CABG with the Left Internal Mammary Artery (LIMA):
Because of its longevity and favorable effects on long-term results, the left internal mammary artery is frequently the conduit of choice for CABG surgeries. The total benefit of CABG may be lessened if LIMA is not part of the surgical plan, and other options, such as PCI, may need to be taken into account.

Also Read: High-Yield NEET SS Medicine Nephrology Questions

Hope you found this blog helpful for your NEET SS Nephrology Preparation. For more informative and interesting posts like these, keep reading PrepLadder’s blogs.